Menu

Report: Boost Funds for Basic Science in Canada

An independent review of Canadian science reveals a need for additional funds to investigator-led, basic research.

Apr 11, 2017
Diana Kwon

FLICKR, KMR PHOTOGRAPHY

Canada needs to support science with a C$1.3 billion boost in funding to inquiry driven, basic research over the next four years, according to a report on the country’s research and innovation landscape, released this week (April 10).

The report outlines a review conducted by a nine-person panel, commissioned last summer by Canada’s Science Minister Kristy Duncan to investigate the state of fundamental research in the country and provide suggestions for improvement.

“A crucial shortcoming in the system is the level of support for independent investigator-initiated research,” David Naylor, a former president of the University of Toronto in Canada who led the panel, told Science. “That support has been squeezed for about a decade.”

According to the panel’s report, a shift toward “targeted or priority-driven” research corresponded with a 35 percent drop in funding per capita to basic researchers in the country since 2013. “These indices leave the Panel certain that meaningful augmentation of federal funding is required for Canada to compete, even with smaller peers such as Australia and Switzerland, let alone with the research machinery in larger and better established nations,” the authors wrote.

The panel also noted that the current system makes it difficult for early-career researchers to obtain funding. “They are really finding it difficult in the present system,” Nobel Laureate Art McDonald, a member of the panel, told The Globe and Mail. “These are enthusiastic young people that should be our next generation of successful scientists and we need to be treating them somewhat better than we have been in recent times.”

To reverse these trends, the panel recommended an increase in science funding from C$3.5 billion to C$4.8 billion over the next four years to its three main research funding agencies—the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, and the Social Sciences and Humanities Research Council of Canada—and the Canada Foundation for Innovation, which supports research infrastructure.

The highest priority, however, is a C$485 million increase in investigator-led basic research. “Restoring the balance . . . is central to reinvigorating Canadian scholarship and science,” Naylor told Science.

The report comes on the heels of Prime Minister Justin Trudeau’s draft budget, in which funds for the three main research councils remains flat. “We have had a war on science in this country,” Kennedy Stewart, who tracks science issues for the New Democratic Party, the left-wing opposition to Trudeau’s middle-left Liberals, told Nature. “We have had lots of rhetoric from this government about reinstating science. Now it has to put its money where its mouth is.”

See “Canadian Researchers Disheartened Over Draft Budget

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.